Controversy and Progress in Alzheimers Disease - FDA Approval of AducanumabNEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Second Drug Okayed for Rare Central Nervous System DiseaseJAMA 324:224, Jaklevic, M.C., 2020